Literature DB >> 8981337

Prevalence of hormone replacement therapy and user's characteristics: a community survey in Japan.

C Nagata1, Y Matsushita, H Shimizu.   

Abstract

OBJECTIVES: It is quite recently that much interest has been paid to the benefits of hormone replacement therapy (HRT) in Japan. We conducted a community survey in Japan in 1992 to examine the prevalence of HRT use and factors related to HRT use.
METHODS: A total of 8791 female residents aged 45-64 years old in a city of the Gifu Prefecture, Japan, responded to the questionnaire including medical and reproductive histories, lifetime occupational history, diet, exercise, smoking and drinking habits, and use of vitamin supplements or medications. The response rate was 94.2%.
RESULTS: Overall, 2.5% of women reported current use of HRT and 6.3% had used HRT previously. The highest prevalence of current use was found among postmenopausal women with surgical menopause (4.8%). Current users were more likely to have participated in cancer screenings, and to have used vitamin supplements or calcium during the past year.
CONCLUSIONS: HRT use rate was 2.5% among female residents aged 45-64 years old in a Japanese community in 1992. Current users may have more regard for their health status.

Entities:  

Mesh:

Year:  1996        PMID: 8981337     DOI: 10.1016/s0378-5122(96)01067-5

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  9 in total

1.  Estimated numbers of postmenopausal women treated by hormone therapy in France.

Authors:  Angèle Gayet-Ageron; Nassira Amamra; Virginie Ringa; Valérie Tainturier; Claudine Berr; Françoise Clavel-Chapelon; Cécile Delcourt; Pierre D Delmas; Pierre Ducimetière; Anne-Marie Schott
Journal:  Maturitas       Date:  2005-06-13       Impact factor: 4.342

2.  Menstrual and reproductive factors and risk of vertebral fractures in Japanese women: the Japan Public Health Center-based prospective (JPHC) study.

Authors:  Y Shimizu; N Sawada; K Nakamura; Y Watanabe; K Kitamura; M Iwasaki; S Tsugane
Journal:  Osteoporos Int       Date:  2018-08-24       Impact factor: 4.507

3.  Postmenopausal breast cancer in Iran; risk factors and their population attributable fractions.

Authors:  Reza Ghiasvand; Shahram Bahmanyar; Kazem Zendehdel; Sedigheh Tahmasebi; Abdolrasoul Talei; Hans-Olov Adami; Sven Cnattingius
Journal:  BMC Cancer       Date:  2012-09-19       Impact factor: 4.430

Review 4.  Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan.

Authors:  H Ohta; J Solanki
Journal:  Osteoporos Int       Date:  2014-12-02       Impact factor: 4.507

5.  Female reproductive factors and risk of lymphoid neoplasm: The Japan Public Health Center-based Prospective Study.

Authors:  Shiori Tanaka; Norie Sawada; Taiki Yamaji; Taichi Shimazu; Atsushi Goto; Motoki Iwasaki; Manami Inoue; Shoichiro Tsugane
Journal:  Cancer Sci       Date:  2019-03-09       Impact factor: 6.716

6.  Associations of Body Mass Index, Weight Change, Physical Activity, and Sedentary Behavior With Endometrial Cancer Risk Among Japanese Women: The Japan Collaborative Cohort Study.

Authors:  Hiromi Miyata; Kokoro Shirai; Isao Muraki; Hiroyasu Iso; Akiko Tamakoshi
Journal:  J Epidemiol       Date:  2021-03-04       Impact factor: 3.211

Review 7.  Dietary calcium intake and change in bone mineral density in older adults: a systematic review of longitudinal cohort studies.

Authors:  Sarah M Bristow; Mark J Bolland; Greg D Gamble; William Leung; Ian R Reid
Journal:  Eur J Clin Nutr       Date:  2021-06-15       Impact factor: 4.016

8.  At what age should screening mammography be recommended for Asian women?

Authors:  Junko Tsuchida; Masayuki Nagahashi; Omar M Rashid; Kazuaki Takabe; Toshifumi Wakai
Journal:  Cancer Med       Date:  2015-04-27       Impact factor: 4.452

9.  Evidence-based medicine and hormone replacement therapy.

Authors:  Abdullah Alkhenizan
Journal:  Ann Saudi Med       Date:  2004 May-Jun       Impact factor: 1.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.